DNA testing could improve outcomes for patients with COVID-19, according to preliminary research posted on bioRxiv. By posting preprints on bioRxiv, authors are able to make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals. At this time, information on COVID-19 research needs to be shared rapidly and openly to inform the global public health response and to help save lives.
In his preprint, Dr Bill Gibson, a BC Children’s Hospital investigator and Professor in the Department of Medical Genetics at the University of British Columbia, discusses why genotyping ACE2 could potentially improve patient care for this disease.
ACE2 is the protein identified as the key point of entry for the new coronavirus into human cells. Dr Gibson and his team have searched genetic databases and identified several variants already present in the human population that could affect how the virus binds the protein and enters the cell. If these variants do influence the severity of the disease it could help clinicians make more informed treatment decisions during the pandemic.
Up till now, there is no direct laboratory evidence that different genetic variants are influencing the course of this disease; however, many countries have observed startling differences in the COVID-19 death rates between men and women. In the USA, men with COVID-19 are dying at twice the rate as women with the disease.
According to Dr Gibson, this could be partly explained by the fact that the gene for ACE2 lies on the X chromosome. Males only have a single version of the gene. If the copy they inherited makes them more susceptible to the virus, then their cells will only express that more susceptible version. As females carry two copies of the gene, any viral susceptibility coming from one variant would be mitigated by the ACE2 protein made from their second ACE2 allele.
There are many other factors that will influence the severity of COVID-19, says Dr Gibson.
“Some portion of this difference between men and women in COVID-19 morbidity and mortality may be genetic, we just don’t know how much”, he said.
The quickest way to find these variants is to examine the ACE2 gene in unusual cases of COVID-19, taking what is known as the ‘extreme phenotypes’ approach. For example, children are less likely to suffer severe disease after being exposed to COVID-19. Therefore, any child with unusually severe COVID-19 (such as requiring ICU care), could, in principle, have this gene sequenced where resources allow, suggests Dr Gibson. However, we would need to add up the data from many, many children and adults before we could be sure that rare ACE2 variants truly affect disease severity, he said.
“What we have right now is a model, and hopefully a useful one. In some places around the world doctors are already making difficult decisions about who to treat and how: a genetic test such as this could arm clinicians with the knowledge they need to intervene earlier in certain cases, and thereby save more lives.”
If you require more information on our DNA testing services you can contact us via Live Chat or call 727-325-2902. Alternatively, further details can be found on our website.